Canadian labelling for all JAK inhibitors to include risks of serious heart-related problems, fatal blood clots and cancer
Critical priority
What you should do
- 1Talk to your health care professional for more details about this new safety information.
- 2Talk to your health care professional about possible heart disease risk factors before starting a JAK inhibitor.
- 3Contact your health care professional immediately and stop taking your JAK inhibitor if you develop symptoms of a heart problem.
- 4Symptoms may include:new or worsening chest pain;shortness of breath;irregular heartbeats; orswelling of the legs.
- 5Talk to your health care professional if you have or have had any type of cancer before taking a JAK inhibitor.
The issue
Labelling
Affected product
Janus Kinase (JAK) inhibitors, including: Cibinqo, Inrebic, Jakavi, Olumiant, Rinvoq and Xeljanz/Xeljanz XR.
Where it was sold
Canada (national)Reported in the official notice — confirm there.
Issued by
Health Canada
Read the official Government of Canada notice
All recallsRecallGuardian ranks, illustrates and rewrites recalls in plain language. The official notice is authoritative — confirm model numbers, lot codes, dates and remedies there.